| pubmed-article:11766078 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11766078 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11766078 | lifeskim:mentions | umls-concept:C0026896 | lld:lifeskim |
| pubmed-article:11766078 | lifeskim:mentions | umls-concept:C0289793 | lld:lifeskim |
| pubmed-article:11766078 | lifeskim:mentions | umls-concept:C1171362 | lld:lifeskim |
| pubmed-article:11766078 | lifeskim:mentions | umls-concept:C0004358 | lld:lifeskim |
| pubmed-article:11766078 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:11766078 | lifeskim:mentions | umls-concept:C1515670 | lld:lifeskim |
| pubmed-article:11766078 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:11766078 | pubmed:dateCreated | 2001-12-18 | lld:pubmed |
| pubmed-article:11766078 | pubmed:abstractText | Gravin is expressed in several cell and tissue types as either 300 kDa doublet or 250 kDa proteolytic products. It is a cytoplasmic antigen that reacts with the serum of patients with myasthenia gravis (MG). Autoantibodies to gravin residues 1477-1781 are highly specific for MG. In the present study, we examined residues 1477-1781 in detail and found that residues 1542-1547 of gravin protein, which had sequence homology with the binding sequences of two protein A-kinase anchoring proteins, were highly reactive to MG serum. Antigravin antibody activities were stronger in younger and nonthymomatous patients. These findings suggest that antigravin antibody activities could be a useful prognostic factor and that the gravin antibody of MG may have a function which prevents the protein A-kinase binding pathway. | lld:pubmed |
| pubmed-article:11766078 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11766078 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11766078 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11766078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11766078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11766078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11766078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11766078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11766078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11766078 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11766078 | pubmed:issn | 0941-1291 | lld:pubmed |
| pubmed-article:11766078 | pubmed:author | pubmed-author:SasakiMM | lld:pubmed |
| pubmed-article:11766078 | pubmed:author | pubmed-author:SasakiHH | lld:pubmed |
| pubmed-article:11766078 | pubmed:author | pubmed-author:YamakawaYY | lld:pubmed |
| pubmed-article:11766078 | pubmed:author | pubmed-author:FujiiYY | lld:pubmed |
| pubmed-article:11766078 | pubmed:author | pubmed-author:NonakaMM | lld:pubmed |
| pubmed-article:11766078 | pubmed:author | pubmed-author:KunimatsuMM | lld:pubmed |
| pubmed-article:11766078 | pubmed:author | pubmed-author:KiriyamaMM | lld:pubmed |
| pubmed-article:11766078 | pubmed:author | pubmed-author:FukaeMM | lld:pubmed |
| pubmed-article:11766078 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11766078 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:11766078 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11766078 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11766078 | pubmed:pagination | 1036-7 | lld:pubmed |
| pubmed-article:11766078 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:meshHeading | pubmed-meshheading:11766078... | lld:pubmed |
| pubmed-article:11766078 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11766078 | pubmed:articleTitle | Autoantibody to gravin is expressed more strongly in younger and nonthymomatous patients with myasthenia gravis. | lld:pubmed |
| pubmed-article:11766078 | pubmed:affiliation | Department of Surgery II, Nagoya City University Medical School, Nagoya, Japan. | lld:pubmed |
| pubmed-article:11766078 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:9590 | entrezgene:pubmed | pubmed-article:11766078 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11766078 | lld:pubmed |
